drugset / Trial / NCT06132880
Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)
Not yet recruiting
540 enrolled
Beijing Tsinghua Chang Gung Hospital
Peking University People's Hospital · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The primary purpose of this trial is to evaluate the effects of Human Urinary Kallidinogenase on improvement of neurological outcome, and early cerebral perfusion in acute ischemic stroke.
Timeline
- Start
- 2023-12-14
- Primary completion
- 2026-08-28
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Urinary Kallidinogenase | Protein / enzyme biologic | 0.15 unknown | Intravenous |